Suppr超能文献

髓过氧化物酶的序贯分析用于预测疑似急性冠状动脉缺血后的不良事件

Sequential analysis of myeloperoxidase for prediction of adverse events after suspected acute coronary ischemia.

作者信息

Koch Christian, Henrich Michael, Heidt Martin Clemens

机构信息

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Giessen and Marburg, Giessen, Germany.

出版信息

Clin Cardiol. 2014 Dec;37(12):744-9. doi: 10.1002/clc.22336. Epub 2014 Nov 17.

Abstract

BACKGROUND

Myeloperoxidase (MPO) plasma values predict major adverse cardiac events (MACE) in cases of acute coronary syndrome. The effect of serial testing in patients who are suspected for acute coronary ischemia is unclear.

HYPOTHESIS

We hypothesize that sequential MPO measurement may improve prediction of MACE in patients with suspected acute coronary ischemia.

METHODS

The present prospective observational study examined the prognostic significance of MPO in 917 patients with suspicion of acute coronary syndrome. Blood samples were taken at cardiac catheter laboratory admission and the day after coronary angiography. We recorded patients' mortality, the occurrence of cardiac ischemia, and repeated percutaneous coronary intervention through the next 6 months.

RESULTS

Mortality among patients with increased MPO plasma levels the day after coronary angiography was increased significantly (P < 0.01). Patients with MPO values above 306.3 pmol/L had a significantly higher incidence of 6-month MACE (P < 0.0001) than patients with lower plasma values. Cox proportional hazards multivariate regression analyses revealed that MPO was an independent marker for MACE after suspected acute coronary ischemia (P = 0.048). However, MPO plasma levels at cardiac catheter laboratory admission showed no prognostic significance.

CONCLUSIONS

In patients with suspected myocardial infarction, MPO levels above 306.3 pmol/L measured 24 hours after onset of symptoms were independent predictors of 6-month mortality and MACE.

摘要

背景

髓过氧化物酶(MPO)血浆值可预测急性冠状动脉综合征患者的主要不良心脏事件(MACE)。对于疑似急性冠状动脉缺血患者进行系列检测的效果尚不清楚。

假设

我们假设连续检测MPO可能会改善对疑似急性冠状动脉缺血患者MACE的预测。

方法

本前瞻性观察性研究检测了917例疑似急性冠状动脉综合征患者中MPO的预后意义。在心脏导管实验室入院时及冠状动脉造影后第二天采集血样。我们记录了患者的死亡率、心脏缺血的发生情况以及接下来6个月内重复进行的经皮冠状动脉介入治疗。

结果

冠状动脉造影后第二天MPO血浆水平升高的患者死亡率显著增加(P < 0.01)。MPO值高于306.3 pmol/L的患者6个月MACE发生率显著高于血浆值较低的患者(P < 0.0001)。Cox比例风险多变量回归分析显示,MPO是疑似急性冠状动脉缺血后MACE的独立标志物(P = 0.048)。然而,心脏导管实验室入院时的MPO血浆水平无预后意义。

结论

在疑似心肌梗死患者中,症状发作24小时后测得的MPO水平高于306.3 pmol/L是6个月死亡率和MACE的独立预测指标。

相似文献

1
Sequential analysis of myeloperoxidase for prediction of adverse events after suspected acute coronary ischemia.
Clin Cardiol. 2014 Dec;37(12):744-9. doi: 10.1002/clc.22336. Epub 2014 Nov 17.
2
[Prognostic value of myeloperoxidase concentration in patients with acute coronary syndrome].
Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Apr 24;46(4):284-291. doi: 10.3760/cma.j.issn.0253-3758.2018.04.007.
4
Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain.
Clin Chem. 2011 Dec;57(12):1762-70. doi: 10.1373/clinchem.2011.166827. Epub 2011 Sep 22.
5
Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.
J Am Coll Cardiol. 2007 May 22;49(20):1993-2000. doi: 10.1016/j.jacc.2007.02.040. Epub 2007 May 4.

引用本文的文献

1
Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction.
Antioxidants (Basel). 2024 Jun 28;13(7):788. doi: 10.3390/antiox13070788.
2
Neutrophil degranulation and myocardial infarction.
Cell Commun Signal. 2022 Apr 11;20(1):50. doi: 10.1186/s12964-022-00824-4.
3
Prognostic Role of Elevated Myeloperoxidase in Patients with Acute Coronary Syndrome: A Systemic Review and Meta-Analysis.
Mediators Inflamm. 2019 Jun 25;2019:2872607. doi: 10.1155/2019/2872607. eCollection 2019.

本文引用的文献

3
Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review.
Am Heart J. 2013 Apr;165(4):441-50. doi: 10.1016/j.ahj.2012.12.020. Epub 2013 Feb 16.
5
Prognostic impact of hospital readmissions after primary percutaneous coronary intervention.
Arch Intern Med. 2011 Nov 28;171(21):1948-9. doi: 10.1001/archinternmed.2011.536.
6
Myeloperoxidase in the diagnosis of acute coronary syndromes: the importance of spectrum.
Am Heart J. 2011 Nov;162(5):893-9. doi: 10.1016/j.ahj.2011.08.017.
7
Long-term prognostic value of myeloperoxidase on acute coronary syndrome: a meta-analysis.
Arch Med Res. 2011 Jul;42(5):368-74. doi: 10.1016/j.arcmed.2011.07.004. Epub 2011 Jul 29.
8
Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations.
Clin Chem. 2011 Apr;57(4):603-8. doi: 10.1373/clinchem.2010.158014. Epub 2011 Jan 24.
10
Myeloperoxidase is not useful for the early assessment of patients with chest pain.
Clin Biochem. 2010 Feb;43(3):240-5. doi: 10.1016/j.clinbiochem.2009.09.026. Epub 2009 Oct 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验